Programs

OUR PROGRAMS

Our lead program is a proprietary extended-release formulation of a well-known analgesic drug with anti-inflammatory properties. Sollis’ innovative formulation is designed to deliver a non-opioid, non-steroid compound directly to the lumbar epidural space to treat lumbosacral radiculopathy (sciatica), a severely painful condition that affects up to 40% of people at some point during their lives.